newsfilter
← Latest News
Business Wire·

Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones

- Topline data from PIPE-791 Phase 1b positron emission tomography (PET) trial expected in the second quarter of 2025 - Topline data from PIPE-307 Phase 2 VISTA trial for the treatment of relapsing-remitting multiple